Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H27O5S.Na |
| Molecular Weight | 390.469 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC=C4C[C@H](CC[C@]34C)OS([O-])(=O)=O
InChI
InChIKey=GFJWACFSUSFUOG-ZJTJBYBXSA-M
InChI=1S/C19H28O5S.Na/c1-18-9-7-13(24-25(21,22)23)11-12(18)3-4-14-15-5-6-17(20)19(15,2)10-8-16(14)18;/h3,13-16H,4-11H2,1-2H3,(H,21,22,23);/q;+1/p-1/t13-,14-,15-,16-,18-,19-;/m0./s1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003687 |
http://www.hmdb.ca/metabolites/HMDB00077
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003687 |
http://www.hmdb.ca/metabolites/HMDB00077
Dehydroepiandrosterone (INTRAROSA™, prasterone) is a major C19 steroid produced from cholesterol by the adrenal cortex. It is also produced in small quantities in the testis and the ovary. Dehydroepiandrosterone (INTRAROSA, prasterone) is structurally similar to, and is a precursor of, androstenedione, testosterone, estradiol, estrone and estrogen. It indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. The mechanism of action of dehydroepiandrosterone (INTRAROSA, prasterone) in postmenopausal women with vulvar and vaginal atrophy is not fully established.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL242 |
514.55 nM [Ki] | ||
Target ID: CHEMBL206 |
1053.17 nM [Ki] | ||
Target ID: CHEMBL1871 |
1177.02 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | INTRAROSA Approved UseINTRAROSA™ is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. Launch Date2016 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
36.7 nM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10372727 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRASTERONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
176.1 nM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10372727 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRASTERONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.35 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10372727 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRASTERONE serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1600 mg 1 times / day multiple, oral Highest studied dose Dose: 1600 mg, 1 times / day Route: oral Route: multiple Dose: 1600 mg, 1 times / day Sources: |
healthy, 22-25 years n = 5 Health Status: healthy Age Group: 22-25 years Sex: M Population Size: 5 Sources: |
|
400 mg 1 times / day multiple, oral Dose: 400 mg, 1 times / day Route: oral Route: multiple Dose: 400 mg, 1 times / day Sources: |
unhealthy, 44.9 years n = 29 Health Status: unhealthy Condition: HIV infection Age Group: 44.9 years Sex: M Population Size: 29 Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no | ||||
| no |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes | ||||
| yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The effect of ultraviolet radiation and pretreatment of dehydroepiandrosterone on RMK cells in culture. | 2001 |
|
| The use of estrogen, DHEA, and diosgenin in a sustained delivery setting as a novel treatment approach for osteoporosis in the ovariectomized adult rat model. | 2001 |
|
| The prevention of osteoporotic progression by means of steroid loaded TCPL drug delivery systems. | 2001 |
|
| Intraadrenal mechanisms of DHEA regulation: a hypothesis for adrenopause. | 2001 |
|
| GG-genotype in the promotor region of uncoupling-protein-1 gene is associated with lower level of dehydroepiandrosterone in type 2 diabetes. | 2001 |
|
| Increased serum cortisol levels are associated with high tumour grade in patients with renal cell carcinoma. | 2001 |
|
| Effects of transdermal application of 7-oxo-DHEA on the levels of steroid hormones, gonadotropins and lipids in healthy men. | 2001 |
|
| Hyposecretion of the adrenal androgen dehydroepiandrosterone sulfate and its relation to clinical variables in inflammatory arthritis. | 2001 |
|
| Therapeutic strategies in adrenal insufficiency. | 2001 Apr |
|
| Sex hormones and their impact on dementia and depression: a clinical perspective. | 2001 Apr |
|
| [Correlations between acne and polycystic ovary. A study of 60 cases]. | 2001 Apr |
|
| High-grade prostate cancer is associated with low serum testosterone levels. | 2001 Apr |
|
| Up-regulation of cyclooxygenase-1 in neuroblastoma cell lines by retinoic acid and corticosteroids. | 2001 Apr |
|
| Novel assay for determination of androgen bioactivity in human serum. | 2001 Apr |
|
| Effect of estrogen on serum DHEA in younger and older women and the relationship of DHEA to adiposity and gender. | 2001 Apr |
|
| Sarcopenia. | 2001 Apr |
|
| The adrenal and the metabolic syndrome. | 2001 Apr |
|
| Regulation of calcitonin receptor by glucocorticoid in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor. | 2001 Apr |
|
| Leuprolide acetate treatment of adrenocortical disease in ferrets. | 2001 Apr 15 |
|
| Solvent and solid-phase extraction of natural and synthetic anabolic steroids in human urine. | 2001 Apr 25 |
|
| DHEA: a novel adjunct for the treatment of male trauma patients. | 2001 Feb |
|
| Effect of tauroursodeoxycholate and S-adenosyl-L-methionine on 17beta-estradiol glucuronide-induced cholestasis. | 2001 Feb |
|
| Dehydroepiandrosterone decreases mortality rate and improves cellular immune function during polymicrobial sepsis. | 2001 Feb |
|
| Non-aqueous emulsions: hydrocarbon-formamide systems. | 2001 Feb 19 |
|
| [Replacement therapy in adrenopause. Dehydroepiandrosterone and aging]. | 2001 Jan |
|
| Characteristics of cystic breast disease with special regard to breast cancer development. | 2001 Jan-Feb |
|
| Ergosteroids IV: synthesis and biological activity of steroid glucuronosides, ethers, and alkylcarbonates. | 2001 Jul |
|
| Neurosteroid hydroxylase CYP7B: vivid reporter activity in dentate gyrus of gene-targeted mice and abolition of a widespread pathway of steroid and oxysterol hydroxylation. | 2001 Jun 29 |
|
| Circulating plasma leptin and IGF-1 levels in girls with premature adrenarche: potential implications of a preliminary study. | 2001 Mar |
|
| Exploratory biochemical data analysis: a comparison of two sample means and diagnostic displays. | 2001 Mar |
|
| Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy. | 2001 Mar |
|
| Follicle-stimulating hormone regulates steroidogenic enzymes in cultured cells of the chick embryo ovary. | 2001 Mar |
|
| Association of vitamin D receptor and 17 hydroxylase gene polymorphisms with benign prostatic hyperplasia and benign prostatic enlargement. | 2001 Mar |
|
| Ontogeny of the neurosteroid enzyme Cyp7b in the mouse. | 2001 Mar 28 |
|
| Temporal and spatial distribution of corticosteroidogenic enzymes immunoreactivity in developing human adrenal. | 2001 Mar 28 |
|
| Effect of beta-estradiol on voltage-gated Ca(2+) channels in rat hippocampal neurons: a comparison with dehydroepiandrosterone. | 2001 Mar 30 |
|
| Hormones as antiaging remedies. | 2001 Mar-Apr |
|
| Adrenal steroids in human prostatic cancer cell lines. | 2001 Mar-Apr |
|
| Sebocytes are the key regulators of androgen homeostasis in human skin. | 2001 May |
|
| Regulation of glucocorticoid receptor alpha and beta isoforms and type I 11beta-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? | 2001 May |
|
| Identification of extracellular matrix components and their integrin receptors in the human fetal adrenal gland. | 2001 May |
|
| Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. | 2001 May |
|
| Dehydroepiandrosterone inhibits lipopolysaccharide-induced nitric oxide production in BV-2 microglia. | 2001 May |
|
| Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. | 2001 May |
|
| Influence of culture system and medium enrichment on sulfotransferase and sulfatase expression in male rat hepatocyte cultures. | 2001 May 1 |
|
| Dehydroepiandrosterone restores hepatocellular function and prevents liver damage in estrogen-deficient females following trauma and hemorrhage. | 2001 May 15 |
|
| Metabolism of DHEA by cytochromes P450 in rat and human liver microsomal fractions. | 2001 May 15 |
|
| Human oestrogenic 17beta-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction. | 2001 May 15 |
|
| Serum hormones and the alcohol-breast cancer association in postmenopausal women. | 2001 May 2 |
|
| Anorectic effect of dehydroepiandrosterone combined with dexfenfluramine or thionisoxetine. | 2001 May 4 |
Sample Use Guides
Administer one INTRAROSA vaginal insert once daily at bedtime, using the provided applicator.
Route of Administration:
Vaginal
Dehydroepiandrosterone (DHEA) bound to AR with a Ki of 1 microM, which was associated with AR transcriptional antagonism on both the mouse mammary tumor virus and prostate-specific antigen promoters. DHEA bound to ERalpha and ERbeta, with Ki values of 1.1 and 0.5 microM, respectively. Despite the similar binding affinities, DHEA showed preferential agonism of ERbeta with an EC50 of approximately 200 nm and maximal activation at 1 microM. With ERalpha 30-70% agonism at 5 microM was found.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
102196
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
||
|
FDA ORPHAN DRUG |
101996
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID00273954
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
100000085500
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
B9840IHU4T
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
CHEMBL259898
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
23668320
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
72822
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
Sodium prasterone sulfate
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
1099-87-2
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
214-152-2
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
1366962
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | RxNorm | ||
|
91028
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
SUB04010MIG
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | |||
|
m4145
Created by
admin on Sat Dec 16 01:06:23 GMT 2023 , Edited by admin on Sat Dec 16 01:06:23 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
